NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and ...
Aging and inflammation go hand in hand, so developing a drug to block the inflammation-causing multiprotein complex NLRP3 was ...
Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical ...
Brenig has launched an early Phase 1 trial to evaluate BT-409, its experimental small molecule therapy, in healthy volunteers ...
Northwestern Medicine investigators recently discovered that the mitochondrial respiratory chain — a series of protein complexes essential for a cellular respiration and energy production — is ...
Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and ...
SARS-CoV-2, which belongs to the family Coronaviridae, is a highly infectious virus that mainly infects the respiratory tract of humans. The viral genome of SARS-CoV-2 is found within the nucleocapsid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results